531 related articles for article (PubMed ID: 18347328)
21. Splenic differentiation and emergence of CCR5
Hirako IC; Ataide MA; Faustino L; Assis PA; Sorensen EW; Ueta H; Araújo NM; Menezes GB; Luster AD; Gazzinelli RT
Nat Commun; 2016 Nov; 7():13277. PubMed ID: 27808089
[TBL] [Abstract][Full Text] [Related]
22. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.
Belperio JA; Keane MP; Burdick MD; Lynch JP; Xue YY; Li K; Ross DJ; Strieter RM
J Immunol; 2002 Jul; 169(2):1037-49. PubMed ID: 12097412
[TBL] [Abstract][Full Text] [Related]
23. Plasmodium berghei ANKA infection increases Foxp3, IL-10 and IL-2 in CXCL-10 deficient C57BL/6 mice.
Sarfo BY; Wilson NO; Bond VC; Stiles JK
Malar J; 2011 Mar; 10():69. PubMed ID: 21439091
[TBL] [Abstract][Full Text] [Related]
24. Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome.
Hildebrandt GC; Corrion LA; Olkiewicz KM; Lu B; Lowler K; Duffner UA; Moore BB; Kuziel WA; Liu C; Cooke KR
J Immunol; 2004 Aug; 173(3):2050-9. PubMed ID: 15265940
[TBL] [Abstract][Full Text] [Related]
25. Protein Tyrosine Phosphatase Inhibition Prevents Experimental Cerebral Malaria by Precluding CXCR3 Expression on T Cells.
Van Den Ham KM; Smith LK; Richer MJ; Olivier M
Sci Rep; 2017 Jul; 7(1):5478. PubMed ID: 28710387
[TBL] [Abstract][Full Text] [Related]
26. Nanocurcumin is superior to native curcumin in preventing degenerative changes in Experimental Cerebral Malaria.
Dende C; Meena J; Nagarajan P; Nagaraj VA; Panda AK; Padmanaban G
Sci Rep; 2017 Aug; 7(1):10062. PubMed ID: 28855623
[TBL] [Abstract][Full Text] [Related]
27. Beta interferon suppresses the development of experimental cerebral malaria.
Morrell CN; Srivastava K; Swaim A; Lee MT; Chen J; Nagineni C; Hooks JJ; Detrick B
Infect Immun; 2011 Apr; 79(4):1750-8. PubMed ID: 21245265
[TBL] [Abstract][Full Text] [Related]
28. Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria.
Belnoue E; Potter SM; Rosa DS; Mauduit M; Grüner AC; Kayibanda M; Mitchell AJ; Hunt NH; Rénia L
Parasite Immunol; 2008 Oct; 30(10):544-53. PubMed ID: 18665903
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse.
McPhee CG; Duncan FJ; Silva KA; King LE; Hogenesch H; Roopenian DC; Everts HB; Sundberg JP
J Invest Dermatol; 2012 Jun; 132(6):1736-8. PubMed ID: 22358057
[No Abstract] [Full Text] [Related]
30. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.
Manousou P; Kolios G; Drygiannakis I; Koulentaki M; Pyrovolaki K; Voumvouraki A; Notas G; Bourikas L; Papadaki HA; Kouroumalis E
Clin Exp Immunol; 2013 Apr; 172(1):9-15. PubMed ID: 23480180
[TBL] [Abstract][Full Text] [Related]
31. Minocycline prevents cerebral malaria, confers neuroprotection and increases survivability of mice during Plasmodium berghei ANKA infection.
Apoorv TS; Babu PP
Cytokine; 2017 Feb; 90():113-123. PubMed ID: 27865203
[TBL] [Abstract][Full Text] [Related]
32.
Berretta F; Piccirillo CA; Stevenson MM
Front Immunol; 2019; 10():425. PubMed ID: 30915078
[TBL] [Abstract][Full Text] [Related]
33. Prevention of experimental cerebral malaria by Flt3 ligand during infection with Plasmodium berghei ANKA.
Tamura T; Kimura K; Yuda M; Yui K
Infect Immun; 2011 Oct; 79(10):3947-56. PubMed ID: 21807908
[TBL] [Abstract][Full Text] [Related]
34. Phenylhydrazine administration accelerates the development of experimental cerebral malaria.
Zhu X; Liu J; Feng Y; Pang W; Qi Z; Jiang Y; Shang H; Cao Y
Exp Parasitol; 2015 Sep; 156():1-11. PubMed ID: 26005191
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection.
Wuest TR; Carr DJ
J Immunol; 2008 Dec; 181(11):7985-93. PubMed ID: 19017990
[TBL] [Abstract][Full Text] [Related]
36. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
[TBL] [Abstract][Full Text] [Related]
37. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.
Romagnani P; Rotondi M; Lazzeri E; Lasagni L; Francalanci M; Buonamano A; Milani S; Vitti P; Chiovato L; Tonacchera M; Bellastella A; Serio M
Am J Pathol; 2002 Jul; 161(1):195-206. PubMed ID: 12107104
[TBL] [Abstract][Full Text] [Related]
38. Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis.
Nitcheu J; Bonduelle O; Combadiere C; Tefit M; Seilhean D; Mazier D; Combadiere B
J Immunol; 2003 Feb; 170(4):2221-8. PubMed ID: 12574396
[TBL] [Abstract][Full Text] [Related]
39. CXCR3 ligands contribute to Th1-induced inflammation but not to homing of Th1 cells into the lung.
Manicone AM; Burkhart KM; Lu B; Clark JG
Exp Lung Res; 2008 Sep; 34(7):391-407. PubMed ID: 18716926
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
